NEW YORK (Associated Press) - Biotechnology firm Alnylam Pharmaceuticals Inc. said Tuesday it formed a research partnership with Japan's Takeda Pharmaceutical Co. Ltd. potentially worth more than $1 billion.
The biotech company, which also formed a lucrative $1 billion partnership with Swiss drug maker Roche last year, is developing RNAi, or gene silencing, technology, which uses mechanisms within the body to target and "turn off" certain genes associated with cancer and other diseases.
The biotech company, which also formed a lucrative $1 billion partnership with Swiss drug maker Roche last year, is developing RNAi, or gene silencing, technology, which uses mechanisms within the body to target and "turn off" certain genes associated with cancer and other diseases.
0 comments:
Post a Comment